指南与共识男科与性医学

欧洲泌尿外科学会指南:2021年男性不育症更新

European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility.
指南 / 共识 · Eur Urol · 2021-09-10

欧洲泌尿外科学会(EAU)更新了2021年男性性健康与生殖健康指南,重点总结男性不育症的进展与争议领域。指南基于截至2021年1月的文献综述,对不育夫妇中的男性应进行全面泌尿外科评估以识别可纠正的危险因素,并指出不育男性心血管疾病和癌症风险较高,应进行相应筛查。多数经验性治疗和干预措施证据质量低,需大规模随机对照试验验证。

要点

  • 不育夫妇中的男性应接受全面泌尿外科评估,识别并治疗可纠正的生育损害危险因素。
  • 不育男性心血管疾病和癌症风险较高,应筛查可纠正危险因素如性腺功能减退。
  • 非梗阻性无精子症(NOA)手术首选传统或显微取精术(TESE),睾丸细针定位证据质量低。

核心结论

  • 所有不育男性应接受全面泌尿外科评估,识别并治疗可纠正的危险因素。
  • 不育男性心血管死亡和癌症风险较高,应进行相应筛查和咨询。
  • 经验性治疗和干预措施证据质量低,需大规模随机对照试验验证疗效。

研究设计与样本

  • EAU指南更新,基于截至2021年1月的综合文献综述。
  • 每条推荐均包含强度评级,基于系统文献综述或专家共识。

主要发现

  • 不育男性心血管死亡和癌症风险较高。
  • 精子DNA碎片检测可作为识别不育男性和预测辅助生殖技术结局的新生物标志物。
  • 高促性腺激素性性腺功能减退或性腺功能正常患者激素刺激治疗存在争议,不推荐临床试验外使用。
  • 非梗阻性无精子症(NOA)患者取精术前常规睾丸细针定位证据质量低。

关键数值与推荐

  • 不育男性应筛查可纠正危险因素如性腺功能减退。
  • 高促性腺激素性性腺功能减退或性腺功能正常患者不推荐临床试验外使用激素刺激治疗。
  • 非梗阻性无精子症(NOA)患者手术首选传统或显微取精术(TESE)。
  • 不推荐广泛使用抗氧化剂等经验性治疗和无精子症患者手术取精。

临床怎么用

  • 对不育男性进行综合泌尿外科评估,识别并治疗可纠正的生育损害因素。
  • 对不育男性筛查心血管疾病和癌症风险,并提供适当咨询。
  • 避免常规使用未经验证的经验性治疗和干预措施。
  • 非梗阻性无精子症(NOA)患者选择传统或显微取精术(TESE)作为手术方式。

局限性

  • 支持经验性治疗和干预措施的证据质量低。
  • 睾丸细针定位用于非梗阻性无精子症(NOA)取精前评估的证据质量低。
  • 激素刺激治疗在特定人群中的疗效需大规模随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The European Association of Urology (EAU) has updated its guidelines on sexual and reproductive health for 2021. OBJECTIVE: To present a summary of the 2021 version of the EAU guidelines on sexual and reproductive health, including advances and areas of controversy in male infertility. EVIDENCE ACQUISITION: The panel performed a comprehensive literature review of novel data up to January 2021. The guidelines were updated and a strength rating for each recommendation was included that was based either on a systematic review of the literature or consensus opinion from the expert panel, where applicable. EVIDENCE SYNTHESIS: The male partner in infertile couples should undergo a comprehensive urological assessment to identify and treat any modifiable risk factors causing fertility impairment. Infertile men are at a higher risk of harbouring and developing other diseases including malignancy and cardiovascular disease and should be screened for potential modifiable risk factors, such as hypogonadism. Sperm DNA fragmentation testing has emerged as a novel biomarker that can identify infertile men and provide information on the outcomes from assisted reproductive techniques. The role of hormone stimulation therapy in hypergonadotropic hypogonadal or eugonadal patients is controversial and is not recommended outside of clinical trials. Furthermore, there is insufficient evidence to support the widespread use of other empirical treatments and surgical interventions in clinical practice (such as antioxidants and surgical sperm retrieval in men without azoospermia). There is low-quality evidence to support the routine use of testicular fine-needle mapping as an alternative diagnostic and predictive tool before testicular sperm extraction (TESE) in men with nonobstructive azoospermia (NOA), and either conventional or microdissection TESE remains the surgical modality of choice for men with NOA. CONCLUSIONS: All infertile men should undergo a comprehensive urological assessment to identify and treat any modifiable risk factors. Increasing data indicate that infertile men are at higher risk of cardiovascular mortality and of developing cancers and should be screened and counselled accordingly. There is low-quality evidence supporting the use of empirical treatments and interventions currently used in clinical practice; the efficacy of these therapies needs to be validated in large-scale randomised controlled trials. PATIENT SUMMARY: Approximately 50% of infertility will be due to problems with the male partner. Therefore, all infertile men should be assessed by a specialist with the expertise to not only help optimise their fertility but also because they are at higher risk of developing cardiovascular disease and cancer long term and therefore require appropriate counselling and management. There are many treatments and interventions for male infertility that have not been validated in high-quality studies and caution should be applied to their use in routine clinical practice.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Minhas S, Bettocchi C, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility. Eur Urol. 2021. PMID: 34511305. doi:10.1016/j.eururo.2021.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。